Previous 10 | Next 10 |
WOBURN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. ( Nasdaq: CMRA ), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today will present research demonstrating Comera’s SQ...
WOBURN, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that it has completed its previously announced $4...
Data published in the Journal of Pharmaceutical Sciences support further development of caffeine as a viscosity reducing agent for subcutaneous formulations of monoclonal antibodies WOBURN, Mass., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. ( Nasdaq: CMRA )...
2023-08-10 10:01:52 ET Comera Life Sciences press release ( NASDAQ: CMRA ): Q2 GAAP EPS of -$0.08. Revenue of $315M (+114.3% Y/Y). For further details see: Comera Life Sciences GAAP EPS of -$0.08, revenue of $315M
– Advanced to final stage of technical evaluation in Comera’s research collaboration with Regeneron, a leading U.S. biotechnology company – – Received notice that Nasdaq granted Comera’s request for the continued listing of its common stock...
WOBURN, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. ( Nasdaq: CMRA ), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced a significant expansion of its SQore™...
2023-08-01 08:44:03 ET Life sciences company Comera Life Sciences Holdings ( NASDAQ: CMRA ) said on Tuesday that it is set to complete a $4.1M private placement of shares, and accompanying warrants. The company has executed a definitive agreement to complete the private p...
WOBURN, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that it has executed a definitive agreement to com...
– Ownership of proprietary sourcing for U.S.-manufactured lead SQore excipients allows for full control over supply chain and greater flexibility to support product development needs – WOBURN, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. ...
2023-05-11 11:43:48 ET Comera Life Sciences press release ( NASDAQ: CMRA ): Q1 GAAP EPS of -$0.13. Revenue of $0.39M (-58.9% Y/Y). For further details see: Comera Life Sciences GAAP EPS of -$0.13, revenue of $0.39M
News, Short Squeeze, Breakout and More Instantly...
Comera Life Sciences Holdings Inc. Company Name:
CMRA Stock Symbol:
NASDAQ Market:
Comera Life Sciences Holdings Inc. Website:
DS Smith Plc. (DITHF) is expected to report for Q4 2024 Bluegreen Vacations Holding Corporation - Class B (BVHBB) is expected to report for Q1 2024 Harbour Energy Plc ADR (HBRIY) is expected to report for Q1 2024 Bayerische Motoren Werke AG (BAMXF) is expected to report for Q1 2024 ...
Commercial Metals Company (CMC) is expected to report $1 for Q3 2024 CREATD INC. (CRTD) is expected to report for Q1 2024 GMS Inc. (GMS) is expected to report $2.04 for Q4 2024 China Jo-Jo Drugstores Inc. (CJJD) is expected to report for Q4 2024 Eiger BioPharmaceuticals Inc. (EIGR...
Usinas Siderurgicas De Minas Gerais S.A. ADR (Representing Pref Share Cl A) (USNZY) is expected to report $0 for Q2 2024 CREATD INC. (CRTD) is expected to report for Q1 2024 Bluegreen Vacations Holding Corporation - Class B (BVHBB) is expected to report for Q1 2024 Senstar Technologie...